SUBSCRIBERS
Temasek unit pares stakes in S Korean pharma firms for as much as S$1.36b
Add BT as a preferred sourcePublished Wed, Mar 7, 2018 · 09:50 PM
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
TEMASEK Holdings' unit Ion Investments on Wednesday said it is paring its stakes in two South Korean pharmaceutical companies but will remain a substantial shareholder in both.
Earlier on Tuesday, IFR reported that Ion is selling part of its stakes in Celltrion Inc, and the distributor of its products Celltrion Healthcare.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Autobahn Rent A Car directors declared bankrupt over S$50 million each owed to DBS
Amazon’s MGM Studios gains creative control over ‘James Bond’ franchise
UOB’s Wee Ee Cheong says S$4.9 billion Citi deal ‘paying off’ as Asean push accelerates
In taxing wealth, how far can Singapore push property owners?
